Myomo Q4 revenue falls on lower average selling price

Overview

• Wearable medical robotics firm's Q4 revenue fell 6% yr/yr due to lower ASP

• Company achieved record 241 MyoPro authorizations and orders in Q4

• Introduces 2026 revenue guidance of $43 mln to $46 mln

Outlook

• Myomo expects 2026 revenue between $43 mln and $46 mln

• Company anticipates Q1 2026 revenue of $9 mln to $9.5 mln

• Myomo aims to cut negative free cash flow by half in 2026

Result Drivers

• RECURRING REVENUE - Recurring patient sources accounted for 42% of Q4 revenue, up from 26% in the prior year, driven by U.S. and International O&P providers and MyoConnect referrals

• MARKETING STRATEGY - New marketing strategy with a focus on social media and direct-to-patient advertising launched to support MyoConnect and O&P efforts

• GROSS MARGIN DECLINE - Gross margin declined to 68.6% in Q4 from 71.4% a year ago, due to lower ASP, unfavorable inventory overhead changes, and higher warranty costs

Company press release: ID:nBw262H1sa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.